Sakurai S - Search Results

1

Acute Exacerbation of Anemia with Parvovirus B19 Infection One Year after Sleeve Gastrectomy for Severe Obesity.

Shinzawa T, Usui I, Hanawa K, Kajitani H, Sakurai S, Tomaru T, Iijima T, Jojima T, Kojima K, Aso Y. Shinzawa T, et al. Among authors: sakurai s. Intern Med. 2022 Sep 1;61(17):2631-2635. doi: 10.2169/internalmedicine.8446-21. Epub 2022 Feb 8. Intern Med. 2022. PMID: 35135915 Free PMC article.

2

Evaluation of a Premixed Insulin Analog Suspension in Japanese People with Type 2 Diabetes and the Clinical Importance of Improved Injection Techniques: A Cross-Sectional Pilot Study.

Suzuki K, Aoki C, Kato K, Shimizu M, Sakurai S, Yanagi K, Kuroda H, Aso Y. Suzuki K, et al. Among authors: sakurai s. Diabetes Ther. 2017 Apr;8(2):445-449. doi: 10.1007/s13300-017-0228-9. Epub 2017 Jan 24. Diabetes Ther. 2017. PMID: 28120260 Free PMC article.

3

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.

Aso Y, Kato K, Sakurai S, Kishi H, Shimizu M, Jojima T, Iijima T, Maejima Y, Shimomura K, Usui I. Aso Y, et al. Among authors: sakurai s. Int J Clin Pract. 2019 May;73(5):e13335. doi: 10.1111/ijcp.13335. Epub 2019 Apr 1. Int J Clin Pract. 2019. PMID: 30810254 Clinical Trial.

4

Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report.

Kunii T, Iijima T, Jojima T, Shimizu M, Kase M, Sakurai S, Kogai T, Usui I, Aso Y. Kunii T, et al. Among authors: sakurai s. J Med Case Rep. 2019 Apr 20;13(1):99. doi: 10.1186/s13256-019-2018-7. J Med Case Rep. 2019. PMID: 31003599 Free PMC article.

5

Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.

Aso Y, Kase M, Sagara M, Sakurai S, Iijima T, Tomaru T, Jojima T, Usui I. Aso Y, et al. Among authors: sakurai s. Am J Med Sci. 2020 Sep;360(3):261-267. doi: 10.1016/j.amjms.2020.05.005. Epub 2020 May 11. Am J Med Sci. 2020. PMID: 32540146

6

Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.

Sakurai S, Jojima T, Iijima T, Tomaru T, Usui I, Aso Y. Sakurai S, et al. J Diabetes Complications. 2020 Nov;34(11):107703. doi: 10.1016/j.jdiacomp.2020.107703. Epub 2020 Jul 31. J Diabetes Complications. 2020. PMID: 32883567 Clinical Trial.

7

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication.

Shinohara Y, Iijima T, Sakurai S, Jojima T, Ohira E, Hayashi S, Usui I, Igawa K, Aso Y. Shinohara Y, et al. Among authors: sakurai s. Clin Case Rep. 2020 Aug 30;8(10):2007-2012. doi: 10.1002/ccr3.3047. eCollection 2020 Oct. Clin Case Rep. 2020. PMID: 33088540 Free PMC article.

8

Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report.

Jojima T, Kogai T, Iijima T, Kato K, Sagara M, Kezuka A, Kase M, Sakurai S, Akimoto K, Sakumoto J, Namatame T, Ueki K, Hishinuma A, Kamai T, Usui I, Aso Y. Jojima T, et al. Among authors: sakurai s. Eur J Endocrinol. 2020 Dec;183(6):K7-K12. doi: 10.1530/EJE-20-0014. Eur J Endocrinol. 2020. PMID: 33105102

9

Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.

Jojima T, Sakurai S, Wakamatsu S, Iijima T, Saito M, Tomaru T, Kogai T, Usui I, Aso Y. Jojima T, et al. Among authors: sakurai s. Int J Cardiol. 2021 May 15;331:243-248. doi: 10.1016/j.ijcard.2021.01.063. Epub 2021 Feb 5. Int J Cardiol. 2021. PMID: 33556413 Clinical Trial.

10

Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.

Sagara M, Iijima T, Kase M, Kato K, Sakurai S, Tomaru T, Jojima T, Usui I, Aso Y. Sagara M, et al. Among authors: sakurai s. J Diabetes Complications. 2021 May;35(5):107885. doi: 10.1016/j.jdiacomp.2021.107885. Epub 2021 Feb 6. J Diabetes Complications. 2021. PMID: 33602617

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,135 results

Search Page